Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 2, 2023Blood

First-Line Fixed-Duration Ibrutinib Plus Venetoclax (Ibr+Ven) Versus Chlorambucil Plus Obinutuzumab (Clb+O): 55-Month Follow-up from the Glow Study

View Full Paper
Ask AI
Bookmark
Share

Authors

CMCarol MorenoUniversitat Autònoma de BarcelonaTMTalha MunirQuaid-i-Azam UniversityCOCarolyn OwenUniversity of Calgary

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Moreno et al. (2023) studied this question.

synapsesocial.com/papers/6a03c3cd94ec7ec37ca9cfcahttps://doi.org/10.1182/blood-2023-177713
View Full Paper
Ask AI
Bookmark
Share